Table 2.

Inhibition of AspH variants by 2OG oxygenase inhibitors.

Entry	Inhibitor	AspH variant	IC50 [μM][a]
1	MnCl2	wt [17]	5.1±1.1
		H679A	23.1±8.6
		H725A	>40
2	CoCl2	wt [17]	0.4±0.2
		H679A	1.5±0.2
		H725A	3.0±0.5
3	NiSO4	wt [17]	0.17±0.08
		H679A	2.7±0.4
		H725A	1.8±0.4
4	Zn(OAc)2	wt [17]	0.05±0.01
		H679A	0.16±0.01
		H725A	0.16±0.01
5	N‐oxalyl‐glycine (NOG)	wt [17]	1.1±0.3
		H679A	inactive
		H725A	inactive
6	Pyridine‐2,4‐dicarboxylic acid (2,4‐PDCA)	wt [17]	0.03±0.01
		H679A	0.13±0.01
		H725A	11.2±1.4

[a] Mean of two independent runs (n=2; mean ± SD). H679A/H725A AspH inhibition assays were performed as described in the Supporting Information Section 2 using 0.1 μM AspH variant and 4.0 μM hFX‐EGFD1_86‐124‐4Ser (Supporting Figure S2a); the assays were of good quality as high S/N ratios and Z′‐factors ^[19] (>0.5 for each plate) manifest (Supporting Figure S9).